HIV Type 1 DNA Development during Long-Term Supervised Therapy Interruption
- 1 April 2003
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 19 (4), 259-265
- https://doi.org/10.1089/088922203764969456
Abstract
We studied the pattern of HIV-1 DNA development and the association to other HIV-related factors during long-term supervised therapy interruption (LT-STI). Fifteen patients were treated with long-time protease inhibitor-based antiretroviral therapy (PI-ART). They had HIV-1 RNA at + cell counts of 875 (SD 415) × 106/liter. A real-time polymerase chain reaction, amplifying fragments of the HIV-1 pol gene and the human albumin gene simultaneously, was used to quantify HIV-1 DNA molecules in CD4+ cells. The quantity of HIV-1 DNA in CD4+ cells increased during LT-STI in all 15 patients, with an average doubling time of 2 months. Tentatively, three patterns were observed: rapid initial increase with subsequent stabilizing levels, rapid continuous increase, and slow increase. The HIV-1 DNA slope was positively related to the HIV-1 RNA maximum and steady state level and the baseline HIV-1 DNA value. It was inversely related to the decrease in CD4+ cells both before the start of PI-ART and during the LT-STI. To conclude, HIV-1 DNA persists in infected CD4+ cells despite long-term effective PI-ART and will increase after therapy interruption. The most important clinical predictor of long-term STI failure was the rapid CD4+ cell decline before PI-ART. In patients with a steep pre-PI-ART slope it may be prudent to continue treatment and not initiate therapy interruption.Keywords
This publication has 34 references indexed in Scilit:
- HIV-1 DNA Burden in Peripheral Blood CD4+Cells Influences Disease Progression, Antiretroviral Efficacy, and CD4+T-Cell RestorationViral Immunology, 2001
- Decay of HIV Type 1 DNA and Development of Drug-Resistant Mutants in Patients with Primary HIV Type 1 Infection Receiving Highly Active Antiretroviral TherapyAIDS Research and Human Retroviruses, 2001
- Clinical and Immunological Benefits from Highly Active Antiretroviral Therapy in Spite of Limited Viral Load Reduction in HIV Type 1 InfectionAIDS Research and Human Retroviruses, 2001
- HIV RNA and HIV DNA in Peripheral Blood Mononuclear Cells Are Consistent Markers for Estimating Viral Load in Patients Undergoing Long-Term Potent TreatmentAIDS Research and Human Retroviruses, 2000
- British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapyHIV Medicine, 2000
- Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with 500 × 106/l CD4 cells treated with highly active antiretroviral therapyAIDS, 2000
- Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infectionAIDS, 1998
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- Different localization of epstein-barr virus genome in two subclones of the burkitt lymphoma cell line namalwaGenes, Chromosomes and Cancer, 1992